Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 3/20 | 0.46 |
| ▸ | NR1H3 | Q13133 | 3/20 | 0.46 |
| ▸ | RORC | P51449 | 2/20 | 0.45 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.44 |
| ▸ | RIPK1 | Q13546 | 5/20 | 0.42 |
| ▸ | PDK1 | Q15118 | 2/20 | 0.41 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.41 |
| ▸ | PDK3 | Q15120 | 2/20 | 0.41 |
| ▸ | PDK4 | Q16654 | 2/20 | 0.41 |
| ▸ | TACR1 | P25103 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25328193 | 0.89 | TACR1 (0.41) | NR1H2NR1H3RORCABHD6TACR1 | |
| SCHEMBL25917992 | 0.89 | TACR1 (0.41) | NR1H2NR1H3RORCABHD6TACR1 | |
| SCHEMBL25327155 | 0.86 | RIPK1 (0.39) | NR1H2NR1H3RORCABHD6RIPK1 | |
| SCHEMBL25325443 | 0.85 | RIPK1 (0.53) | NR1H2NR1H3RORCABHD6RIPK1 | |
| SCHEMBL25325447 | 0.85 | RIPK1 (0.53) | NR1H2NR1H3RORCABHD6RIPK1 | |
| SCHEMBL25326910 | 0.85 | RIPK1 (0.44) | RIPK1PDK1PDK2PDK3PDK4 | |
| SCHEMBL25326983 | 0.84 | NR1H2 (0.48) | NR1H2NR1H3RORCABHD6RIPK1 | |
| SCHEMBL25326986 | 0.84 | NR1H2 (0.48) | NR1H2NR1H3RORCABHD6RIPK1 | |
| SCHEMBL25916652 | 0.83 | NR1H2 (0.46) | NR1H2NR1H3RORCABHD6RIPK1 | |
| SCHEMBL12668388 | 0.83 | NR1H2 (0.56) | NR1H2NR1H3RORCABHD6RIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250282749-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2025-09-11 | — | — | US | disclosed |
| EP-4469445-A1 | COMPOUNDS AND METHODS OF USE | Tango Therapeutics, Inc. (US) | 2024-12-04 | — | — | EP | disclosed |
| WO-2023146991-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250282749-A1 | COMPOUNDS AND METHODS OF USE | CYP1B1, CYP2C19, UGT1A1 | NR1H2 271/4885NR1H3 252/4885RORC 641/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.